Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023.
August 26, 2023
Share
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023. These A Shares will be under lockup for 1837 days starting from 16-AUG-2018 to 27-AUG-2023.
Details:
The company?s actual controllers and controlling shareholders, Liu Jianhua and Wang Xijuan, as well as their controlled companies, Puhua Enterprises Co., Ltd and Muren Investments Co., Ltd. committed to not dispose off their holdings in the company for a period of 36 months from the date of listing of the new shares, and post the expiration of the 36 month period, to not dispose off, more than, 25% of their holdings annually.
The director and management personnel Cheng Zhaoran and other shareholders, Beijing Workers Investments, Co., Ltd., Nanhai Chengzhang Co., Ltd., Xue Xiaohong, Tan Jiapeng, Nai Ensi, Qu Ping, Liang Xiin and Cheng Zheng committed to not dispose off its holding in the firm for a period of 12 months from the date of listing of the new shares, and post the expiration of the 12 month period, to not dispose off more than 25% of their holdings annually.
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Companyâs present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.